

CRAYVALLAC® WF-9200**1. PRODUCT AND COMPANY IDENTIFICATION****Company**

Arkema Inc.
900 First Avenue
King of Prussia, Pennsylvania 19406

Arkema Coating Resins

Customer Service Telephone Number: (877) 331-6696
(Monday through Friday, 8:00 AM to 5:00 PM EST)

Emergency Information

Transportation: CHEMTREC: (800) 424-9300
(24 hrs., 7 days a week)
Medical: Rocky Mountain Poison Center: (866) 767-5089
(24 hrs., 7 days a week)

Product Information

Product name: CRAYVALLAC® WF-9200
Synonyms: Not available
Molecular formula: Complex Mixture
Chemical family: Micronized wax
Product use: Additive for : , Paints, Coatings, Inks, Adhesives

2. HAZARDS IDENTIFICATION**Emergency Overview**

Color: off-white
Physical state: solid
Form: powder
Odor: odourless

***Classification of the substance or mixture:**
See Supplemental Hazard Statements below.

GHS-Labeling

Signal word: **Warning**

Hazard statements:

This material is considered hazardous under the OSHA Hazard Communication Standard criteria, based on hazard(s) not otherwise classified.

Supplemental Hazard Statements:

CRAYVALLAC® WF-9200

May form combustible dust concentrations in air.
 Processing may release vapors and/or fumes which cause eye, skin and respiratory tract irritation.

Supplemental information:

Potential Health Effects:

The product, in the form supplied, is not anticipated to produce significant adverse human health effects. Mechanical irritation effects from dust exposure are possible at ambient temperature. Contains high molecular weight polymer(s). Decomposition gives toxic and corrosive products. Effects due to processing releases: Irritating to eyes, respiratory system and skin. Inhalation of fume may cause flu-like symptoms. Prolonged or repeated exposure may cause: headache, drowsiness, nausea, weakness, (severity of effects depends on extent of exposure).

Other:

Handle in accordance with good industrial hygiene and safety practice. (powder) This product may release fume and/or vapor of variable composition depending on processing time and temperature. Hazardous decomposition products including toxic and corrosive hydrogen fluoride may be liberated during processing at high temperatures (effects may not be immediately painful or visible).

3. COMPOSITION/INFORMATION ON INGREDIENTS

Chemical Name	CAS-No.	Wt/Wt	GHS Classification**
Ethene, homopolymer	9002-88-4	>= 90 - <= 100 %	Not classified
Proprietary processing aid	Proprietary*	>= 5 - < 10 %	Not classified

*The specific chemical identity is withheld because it is trade secret information of Arkema Inc.

**For the full text of the H-Statements mentioned in this Section, see Section 16.

4. FIRST AID MEASURES

4.1. Description of necessary first-aid measures:

Inhalation:

If inhaled, remove victim to fresh air.

CRAYVALLAC® WF-9200**Skin:**

In case of contact, immediately flush skin with plenty of water. If molten polymer gets on the skin, cool rapidly with cold water. Do not peel solidified product off the skin. Obtain medical treatment for thermal burns. Remove material from clothing. Wash clothing before reuse. Thoroughly clean shoes before reuse.

Eyes:

Immediately flush eye(s) with plenty of water. Obtain medical treatment for thermal burns.

Ingestion:

If swallowed, DO NOT induce vomiting. Get medical attention immediately. If victim is fully conscious, give a cupful of water. Never give anything by mouth to an unconscious person.

4.2. Most important symptoms/effects, acute and delayed:

For most important symptoms and effects (acute and delayed), see Section 2 (Hazard Statements and Supplemental Information if applicable) and Section 11 (Toxicology Information) of this SDS.

4.3. Indication of immediate medical attention and special treatment needed, if necessary:

Unless otherwise noted in Notes to Physician, no specific treatment noted; treat symptomatically.

Notes to physician:

If thermal decomposition of this product occurs releasing HF, additional first aid measures are required. HF decomposition by-product is extremely corrosive and can cause severe burns which may not be immediately visible or painful. Exposure to HF may be fatal if absorbed through the skin, inhaled or swallowed. In all cases of major hydrogen fluoride exposure (including skin burns about the size of the palm of the hand) hypocalcemia may be present. Monitor calcium levels frequently and EKG for signs of calcium depletion. Patients with burns of the neck or face, or with signs of respiratory irritation, should be monitored for delayed pulmonary edema, and edema of the upper airway with respiratory obstruction. Respiratory care should be closely supervised and may include further administration of 2.5% calcium gluconate by nebulization. Do not administer anesthetics after skin contact as the level of pain is an indication of the effectiveness of the calcium gluconate treatment. If pain continues longer than 30 minutes, consider injecting calcium gluconate (5%) into the skin and subcutaneous tissue beneath, around and within the affected area. If swallowed, DO NOT induce vomiting. Administer 4 to 8 ounces of water followed by 2 to 4 ounces of an antacid containing calcium or magnesium.

5. FIREFIGHTING MEASURES**Extinguishing media (suitable):**

Water spray

Extinguishing media (unsuitable):

High volume water jet

Protective equipment:

Fire fighters and others who may be exposed to products of combustion should wear full fire fighting turn out gear (full Bunker Gear) and self-contained breathing apparatus (pressure demand / NIOSH approved or equivalent).

Further firefighting advice:

Do not use a solid stream of water.

A solid stream of water can cause a dust explosion.

Fire fighting equipment should be thoroughly decontaminated after use.

CRAYVALLAC® WF-9200

Fire and explosion hazards:

Dust clouds generated during handling and/or storage can form explosive mixtures with air. Dust explosion characteristics vary with the particle size, particle shape, moisture content, contaminants, and other variables. Note: Check that all equipment is properly grounded and installed to satisfy electrical classification requirements. As with any dry material, pouring this material or allowing it to free-fall or to be conveyed through chutes or pipes can accumulate and generate electrostatic sparks, potentially causing ignition of the material itself, or of any flammable materials which may come into contact with the material or its container.

When burned, the following hazardous products of combustion can occur:

Carbon oxides
Hydrogen fluoride
Hazardous organic compounds

6. ACCIDENTAL RELEASE MEASURES**Personal precautions, Emergency procedures, Methods and materials for containment/clean-up:**

Prevent further leakage or spillage if you can do so without risk. Evacuate area of all unnecessary personnel. Ventilate the area. Eliminate all ignition sources. Avoid dust formation and dispersal of dust in the air. Wet down (dampen) the spilled material with water. Sweep or scoop up using non-sparking tools and place into suitable properly labeled containers for prompt disposal. The sweepings should be wetted down further with water. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Implement workplace practices such that dusts are not allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Consult a regulatory specialist to determine appropriate state or local reporting requirements, for assistance in waste characterization and/or hazardous waste disposal and other requirements listed in pertinent environmental permits.

Protective equipment:

Appropriate personal protective equipment is set forth in Section 8.

7. HANDLING AND STORAGE**Handling****General information on handling:**

Avoid breathing dust.
Keep away from heat, sparks and flames.
Keep container closed.
Avoid creating dust in handling, transfer or clean up.
Prevent dust accumulation.
Implement routine housekeeping practices to ensure that dusts do not accumulate on surfaces.
Check that all equipment is properly grounded and installed to satisfy electrical classification requirements.
Dry powders can build static electricity charges when subjected to the friction of transfer and mixing operations.
Container hazardous when empty.
Follow label warnings even after container is emptied.
RESIDUAL DUSTS MAY EXPLODE ON IGNITION.
DO NOT CUT, DRILL, GRIND, OR WELD ON OR NEAR THIS CONTAINER.
Improper disposal or reuse of this container may be dangerous and/or illegal.
Emptied container retains product residue.
Handle in accordance with good industrial hygiene and safety practices. These practices include avoiding unnecessary exposure and removal of material from eyes, skin, and clothing.

CRAYVALLAC® WF-9200

Storage

General information on storage conditions:

Keep in a dry, cool place. Store in closed containers, in a secure area to prevent container damage and subsequent spillage. Store in well ventilated area away from heat and sources of ignition such as flame, sparks and static electricity. Ensure that all storage and handling equipment is properly grounded and installed to satisfy electrical classification requirements. Static electricity may accumulate when transferring material. All metal and groundable storage containers, including but not limited to drums, cylinders, Returnable Intermodal Bulk Containers (RIBCs) and Class C Flexible Intermodal Bulk Containers (FIBCs) must be bonded and grounded during filling and emptying operations. Observe all federal, state and local regulations and National Fire Protection Association (NFPA) Codes, which pertain to the specific local conditions of storage and use, including NFPA 654.

Storage incompatibility – General:

Store separate from:
Strong oxidizing agents

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Airborne Exposure Guidelines:

Ethene, homopolymer (9002-88-4)

US. ACGIH Threshold Limit Values

Form:	Inhalable particles.
Time weighted average	10 mg/m ³
Form:	Respirable particles.
Time weighted average	3 mg/m ³

US. OSHA Table Z-3 (29 CFR 1910.1000)

Form:	Respirable fraction.
Time weighted average	5 mg/m ³

US. OSHA Table Z-3 (29 CFR 1910.1000)

Form:	Total dust
Time weighted average	50 millions of particles per cubic foot of air

US. OSHA Table Z-3 (29 CFR 1910.1000)

Form:	Total dust
Time weighted average	15 mg/m ³

US. OSHA Table Z-3 (29 CFR 1910.1000)

Form:	Respirable fraction.
Time weighted average	15 millions of particles per cubic foot of air



SAFETY DATA SHEET

CRAYVALLAC® WF-9200

US. OSHA Table Z-1 Limits for Air Contaminants (29 CFR 1910.1000)

Form: Respirable fraction.
PEL: 5 mg/m³

US. OSHA Table Z-1 Limits for Air Contaminants (29 CFR 1910.1000)

Form: Total dust
PEL: 15 mg/m³

Only those components with exposure limits are printed in this section. Limits with skin contact designation above have skin contact effect. Air sampling alone is insufficient to accurately quantitate exposure. Measures to prevent significant cutaneous absorption may be required. Limits with a sensitizer designation above mean that exposure to this material may cause allergic reactions.

Engineering controls:

Investigate engineering techniques to reduce exposures below airborne exposure limits or to otherwise reduce exposures. Provide ventilation if necessary to minimize exposures or to control exposure levels to below airborne exposure limits (if applicable see above). If practical, use local mechanical exhaust ventilation at sources of air contamination such as open process equipment.

Check that all dust control equipment such as local exhaust ventilation, material transport systems, and air-material separation devices involved in handling this product contain explosion relief vents or an explosion suppression system or an oxygen-deficient environment. Isolation devices may be appropriate to prevent propagation from one unit to another. Ensure that dust-handling systems are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment). Consult ACGIH ventilation manual, NFPA Standard 91 and NFPA Standard 654 for design of exhaust system and safe handling.

Respiratory protection:

Avoid breathing dust. Where airborne exposure is likely or airborne exposure limits are exceeded (if applicable, see above), use NIOSH approved respiratory protection equipment appropriate to the material and/or its components and substances released during processing. Consult respirator manufacturer to determine appropriate type equipment for a given application. Observe respirator use limitations specified by NIOSH or the manufacturer. For emergency and other conditions where there may be a potential for significant exposure or where exposure limit may be significantly exceeded, use an approved full face positive-pressure, self-contained breathing apparatus or positive-pressure airline with auxiliary self-contained air supply. Respiratory protection programs must comply with 29 CFR § 1910.134.

Skin protection:

Processing of this product releases vapors or fumes which may cause skin irritation. Minimize skin contamination by following good industrial hygiene practice. Wearing protective gloves is recommended. Wash hands and contaminated skin thoroughly after contact with processing fumes or vapors. Wash thoroughly after handling. NOTE: In the event of thermal decomposition resulting in an HF exposure or release, decontamination of the equipment involves the use of protective equipment. Contact an Industrial Hygienist or safety personnel for type of equipment necessary.

Eye protection:

Product code: 800482

Version 1.0

Issued on: 01/14/2019

Page: 6 / 12

CRAYVALLAC® WF-9200

Use good industrial practice to avoid eye contact. Processing of this product releases vapors or fumes which may cause eye irritation. Where eye contact may be likely, wear chemical goggles and have eye flushing equipment available.

9. PHYSICAL AND CHEMICAL PROPERTIES

Color:	off-white
Physical state:	solid
Form:	powder
Odor:	odourless
Odor threshold:	No data available.
Flash point	> 149 °F (65 °C) (Method: Seta Flash Method)
Auto-ignition temperature:	No data available.
Lower flammable limit (LFL):	No data available.
Upper flammable limit (UFL):	No data available.
pH:	No data available.
Density:	1.07 g/cm ³ (68 °F (20 °C))
Specific Gravity (Relative density):	1.07 (68 °F(20 °C))Water=1 (liquid)
Vapor pressure:	No data available.
Vapor density:	No data available.
Boiling point/boiling range:	No data available.
Melting point/range:	No data available.
Freezing point:	No data available.
Evaporation rate:	No data available.
Solubility in water:	insoluble
Viscosity, dynamic:	No data available.
Oil/water partition coefficient:	No data available.

CRAYVALLAC® WF-9200

Thermal decomposition: No data available.

Flammability: See GHS Classification in Section 2 if applicable

10. STABILITY AND REACTIVITY**Stability:**

This material is chemically stable under normal and anticipated storage, handling and processing conditions.

Hazardous reactions:

Hazardous polymerization does not occur.

Materials to avoid:

Strong oxidizing agents

Conditions / hazards to avoid:

Keep away from heat and sources of ignition. Avoid moisture.

Hazardous decomposition products:

Thermal decomposition giving flammable and toxic products :

Carbon oxides

Hydrogen fluoride

Hazardous organic compounds

11. TOXICOLOGICAL INFORMATION

Data on this material and/or its components are summarized below.

Data for Ethene, homopolymer (9002-88-4)**Acute toxicity****Oral:**

No deaths occurred. (rat) LD50 > 5,000 mg/kg.

Dermal:

No deaths occurred. (rat) LD0 > 2,000 mg/kg.

Skin Sensitization:

Not a sensitizer. Repeated skin exposure. (human subjects) No skin allergy was observed

Repeated dose toxicity

Intratracheal administration to animal / affected organ(s): lung / signs: fibrosis / (dust)

Dietary administration to dog / No adverse effects reported. (Solvent extracts were tested.)

Dietary administration to rat / affected organ(s): liver / (Solvent extracts were tested.)

Carcinogenicity

CRAYVALLAC® WF-9200

Chronic implantation administration to rat, mouse, hamster / signs: tumors at the site of application / Increased incidence of tumors was reported.
Classified by the International Agency for Research on Cancer as: Group 3: Unclassifiable as to carcinogenicity in humans.

Genotoxicity**Assessment in Vitro:**

No genetic changes were observed in a laboratory test using: bacteria

Other information

The information presented is from representative materials with this Chemical Abstract Service (CAS) Registry number. The results vary depending on the size and composition of the test substance.

Human experience**Inhalation:**

Upper respiratory tract: asthma-like symptoms. (based on reports of occupational exposure to workers) (releases from hot processing)

Data for Proprietary processing aid (Proprietary)**Acute toxicity****Oral:**

Practically nontoxic. (rat) LD50 > 5,000 mg/kg.

Skin Irritation:

Not irritating. (rabbit)

Eye Irritation:

Not irritating. (rabbit)

Repeated dose toxicity

Repeated dietary administration to rat / No adverse systemic effects reported.

Carcinogenicity

Chronic subcutaneous injection administration to rat and mouse / signs: tumors at the site of application
Classified by the International Agency for Research on Cancer as: Group 3: Unclassifiable as to carcinogenicity in humans.

Other information

The information presented is from representative materials with this Chemical Abstract Service (CAS) Registry number. The results vary depending on the size and composition of the test substance.

Human experience**Skin contact:**

Non-irritating.

No skin allergy was observed. (studied using human volunteers)

12. ECOLOGICAL INFORMATION**Chemical Fate and Pathway**

CRAYVALLAC® WF-9200

No data are available.

Ecotoxicology

No data are available.

13. DISPOSAL CONSIDERATIONS

Waste disposal:

Where possible recycling is preferred to disposal or incineration. Dispose of in an approved landfill if allowed locally. Incinerate only if the incinerator is fitted to scrub out hydrogen fluoride and other acidic combustion gases. Dispose of in a permitted waste management facility if incineration or landfill is not practical. Pigmented, filled and/or solvent laden product may require special disposal practices in accordance with federal, state and local regulations. Dispose of in accordance with federal, state and local regulations. Consult a regulatory specialist to determine appropriate state or local reporting requirements, for assistance in waste characterization and/or hazardous waste disposal and other requirements listed in pertinent environmental permits. Note: Chemical additions to, processing of, or otherwise altering this material may make this waste management information incomplete, inaccurate, or otherwise inappropriate. Furthermore, state and local waste disposal requirements may be more restrictive or otherwise different from federal laws and regulations.

14. TRANSPORT INFORMATION

US Department of Transportation (DOT): not regulated

International Maritime Dangerous Goods Code (IMDG): not regulated

15. REGULATORY INFORMATION

Chemical Inventory Status

US. Toxic Substances Control Act	TSCA	The components of this product are all on the TSCA Inventory.
Australia. Industrial Chemical (Notification and Assessment) Act	AICS	Conforms to
Canada. Canadian Environmental Protection Act (CEPA). Domestic Substances List (DSL)	DSL	All components of this product are on the Canadian DSL
Japan. Kashin-Hou Law List	ENCS (JP)	Conforms to
Korea. Existing Chemicals Inventory (KECI)	KECI (KR)	Conforms to
Philippines. The Toxic Substances and Hazardous and Nuclear Waste Control Act	PICCS (PH)	Conforms to
China. Inventory of Existing Chemical Substances	IECSC (CN)	Conforms to

CRAYVALLAC® WF-9200

United States – Federal Regulations

SARA Title III – Section 302 Extremely Hazardous Chemicals:

The components in this product are either not SARA Section 302 regulated or regulated but present in negligible concentrations.

SARA Title III - Section 311/312 Hazard Categories:

Fire Hazard

SARA Title III – Section 313 Toxic Chemicals:

This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) - Reportable Quantity (RQ):

The components in this product are either not CERCLA regulated, regulated but present in negligible concentrations, or regulated with no assigned reportable quantity.

United States – State Regulations

New Jersey Right to Know

No components are subject to the New Jersey Right to Know Act.

Pennsylvania Right to Know

<u>Chemical name</u>	<u>CAS-No.</u>
Ethene, homopolymer	9002-88-4

Proprietary processing aid	Proprietary
----------------------------	-------------

California Prop. 65

This product does not contain any chemicals known to the State of California to cause cancer, birth defects, or any other reproductive defects.

16. OTHER INFORMATION

Miscellaneous:

Other information:	Refer to National Fire Protection Association (NFPA) Code 654, Standard for the Prevention of Fire and Dust Explosions from the Manufacturing, Processing, and Handling of Combustible Particulate Solids, for safe handling.
--------------------	---

Latest Revision(s):

Reference number:	200001197
Date of Revision:	01/14/2019
Date Printed:	01/14/2019

CRAYVALLAC® WF-9200

CRAYVALLAC® is a registered trademark of Arkema Inc.

The statements, technical information and recommendations contained herein are believed to be accurate as of the date hereof. Since the conditions and methods of use of the product and of the information referred to herein are beyond our control, ARKEMA expressly disclaims any and all liability as to any results obtained or arising from any use of the product or reliance on such information; **NO WARRANTY OF FITNESS FOR ANY PARTICULAR PURPOSE, WARRANTY OF MERCHANTABILITY OR ANY OTHER WARRANTY, EXPRESSED OR IMPLIED, IS MADE CONCERNING THE GOODS DESCRIBED OR THE INFORMATION PROVIDED HEREIN.** The information provided herein relates only to the specific product designated and may not be applicable when such product is used in combination with other materials or in any process. The user should thoroughly test any application before commercialization. Nothing contained herein constitutes a license to practice under any patent and it should not be construed as an inducement to infringe any patent and the user is advised to take appropriate steps to be sure that any proposed use of the product will not result in patent infringement. See SDS for Health & Safety Considerations.

Arkema has implemented a Medical Policy regarding the use of Arkema products in Medical Devices applications that are in contact with the body or circulating bodily fluids (<http://www.arkema.com/en/social-responsibility/responsible-product-management/medical-device-policy/index.html>) Arkema has designated Medical grades to be used for such Medical Device applications. Products that have not been designated as Medical grades are not authorized by Arkema for use in Medical Device applications that are in contact with the body or circulating bodily fluids. In addition, Arkema strictly prohibits the use of any Arkema products in Medical Device applications that are implanted in the body or in contact with bodily fluids or tissues for greater than 30 days. The Arkema trademarks and the Arkema name shall not be used in conjunction with customers' medical devices, including without limitation, permanent or temporary implantable devices, and customers shall not represent to anyone else, that Arkema allows, endorses or permits the use of Arkema products in such medical devices.

It is the sole responsibility of the manufacturer of the medical device to determine the suitability (including biocompatibility) of all raw materials, products and components, including any medical grade Arkema products, in order to ensure that the final end-use product is safe for its end use; performs or functions as intended; and complies with all applicable legal and regulatory requirements (FDA or other national drug agencies) It is the sole responsibility of the manufacturer of the medical device to conduct all necessary tests and inspections and to evaluate the medical device under actual end-use requirements and to adequately advise and warn purchasers, users, and/or learned intermediaries (such as physicians) of pertinent risks and fulfill any postmarket surveillance obligations. Any decision regarding the appropriateness of a particular Arkema material in a particular medical device should be based on the judgment of the manufacturer, seller, the competent authority, and the treating physician.